RT Journal Article
SR Electronic
T1 A Randomized Clinical Trial of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.12.21264773
DO 10.1101/2021.10.12.21264773
A1 Ridner, Sheila H.
A1 Dietrich, Mary S.
A1 Boyages, John
A1 Koelmeyer, Louise
A1 Elder, Elisabeth
A1 Hughes, T. Michael
A1 French, James
A1 Ngui, Nicholas
A1 Hsu, Jeremy
A1 Abramson, Vandana G.
A1 Moore, Andrew
A1 Shah, Chirag
YR 2021
UL http://medrxiv.org/content/early/2021/10/18/2021.10.12.21264773.abstract
AB Background This study compared rates of progression to chronic breast cancer-related lymphedema (defined as a ≥ 10% arm volume change from baseline requiring complex decongestive physiotherapy (CDP)) following an intervention for subclinical lymphedema (S-BCRL) triggered by bioimpedance spectroscopy (BIS) or by tape measurement (TM).Methods and Results This stratified, randomized, international trial enrolled new breast cancer patients undergoing: mastectomy/partial mastectomy, axillary treatment (dissection, sentinel lymph node biopsy >6 nodes or radiation), radiation therapy (chest wall/ breast, supraclavicular fossa), or taxane-based chemotherapy. Following post-surgery eligibility reassessment, centralized, 1:1 randomization to prospective surveillance by BIS or TM occurred. S-BCRL detection triggered a 4-week, 12-hour per day, compression sleeve and gauntlet intervention. The primary outcome (n=209), rates of post-intervention progression to CDP, were assessed over three years. Between June 24, 2014 and September 11, 2018, 1,200 patients were enrolled, 963 randomized (BIS n=482;TM n=481) and 879 analyzed (BIS n=442;TM n=437). Median follow-up was 32.9 months (IQR=22,35). BIS patients triggered an intervention at a lower rate than TM patients (20.1%, n=89 vs 27.5%, n=120, p = 0.011). Median months to trigger was longer with BIS than TM (9.7; 95%CI,8.2-12.6 vs 3.9; 95%CI,2.8-4.5, p = 0.001). Overall, 14.4%(n=30) progressed post-intervention, with reduced likelihood for BIS patients than TM patients (7.9%, n=7 vs 19.2%, n=23; RR=0.41; 95%CI,0.13-0.81; absolute reduction 11.3%; 95%CI,2.3%-20.3%; p = 0.016).Conclusions As compared to TM, BIS provides a more precise identification of patients likely to benefit from an early compression intervention.Condensed Abstract This stratified, multi-site, international trial enrolled newly diagnosed breast cancer patients, randomized them to prospective surveillance by bioimpedance spectroscopy (BIS) or tape measurement (TM), and screened them for lymphedema development at frequent intervals for three years after surgery. When subclinical lymphedema was detected a 4-week, 12-hour per day, compression sleeve and gauntlet intervention was implemented. Overall, 14.4% (n=30) progressed post-intervention to chronic lymphedema, with reduced likelihood for BIS patients than TM patients (7.9%, n=7 vs 19.2%, n=23; RR=0.41; 95%-CI,0.13-0.81; absolute reduction 11.3%; 95%-CI,2.3%-20.3%; p = 0.016). BIS best supported intervention success for prevention of chronic lymphedema compared to TM.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: SR is the primary investigator and received institutional payment for research from ImpediMed, institutional donation of compression garments from medi and funding from NIH grants to Vanderbilt University, LK and AM received institutional payment for research from ImpediMed and institutional donation of compression garments from medi, JB is an ImpediMed shareholder, LK has been paid for developing and delivering educational presentations for ImpediMed, SR has been paid for developing and delivering educational presentations for Tactile Medical (including travel costs) and Lymphedema Seminars, CS has been paid for developing and delivering educational presentations for TME, CS does consultancy for ImpediMed, PreludeDX, Evicore; no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialNCT02167659Funding StatementThis study was funded by: ImpediMed, medi, and by the National Institutes of Health (NIH/NCATS UL1 TR000445).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Vanderbilt University Institutional Review Board gave ethical approval for this work as the study coordinating center. Each individual site also gave IRB/ethics approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study protocol will be made available at https://nursing.vanderbilt.edu/research/projects/pdf/preventstudy.pdf. The deidentified individual participant data that support the findings will be available at ftp.impedimed.com following an embargo from the date of publication to 12-31-2022 to allow for commercialization of research findings. Data will not be available after 12-31-2023. The ftp site can be accessed using an ftp client such as FileZilla. Username and password can be obtained by contacting sheila.ridner{at}vanderbilt.edu https://ftp.impedimed.com